This study is about testing two different drugs, **Ivonescimab** and **Bevacizumab**, combined with a group of chemotherapy drugs called **FOLFOX** which includes Oxaliplatin, Leucovorin, and 5-Fluorouracil. The study is for people with colorectal cancer that has spread to other parts of the body (metastatic cancer). In this trial, patients will be split into two groups randomly and receive treatments every two weeks. The study will last up to 2 years.

**Eligibility**: To join, participants need to have been diagnosed with metastatic colorectal cancer and have not received prior treatment for it. They must also have a good performance status (ECOG score of 0 or 1) and a life expectancy of at least six months. Some types of cancer or conditions like inflammatory bowel disease or certain genetic mutations mean a person cannot participate.

• The study will have approximately 600 participants.
• Participants will receive treatment every two weeks.
• This trial offers up to 2 years of treatment and monitoring.